Glyxambi Tablet, Film Coated
Product Images NDC 0597-0164

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Glyxambi (NDC 0597-0164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Glyxambi 01

Chemical structure of empagliflozin, one of the active ingredients in Glyxambi tablets, film coated. The structure shows a complex molecule including a glucose moiety and aromatic rings with chlorine and oxygen substituents.*

FDA Label Image

Glyxambi 02

Chemical structure diagram of the active ingredient linagliptin from Glyxambi, showing its molecular framework with rings and functional groups.*

FDA Label Image

Glyxambi 03

A forest plot chart showing the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters AUC and Cmax for various antidiabetic and other drugs. The chart compares changes relative to empagliflozin alone, listing drugs such as Metformin, Glimepiride, Pioglitazone, Sitagliptin, Linagliptin, Simvastatin, Warfarin, Verapamil, Ramipril, Gemfibrozil, Hydrochlorothiazide, Torsemide, Rifampicin, and Probenecid with their dosages and dosing schedules.*

FDA Label Image

Glyxambi 04

A forest plot showing the geometric mean ratio with 90% confidence intervals for various drugs, including antidiabetic drugs (Metformin, Glimepiride, Pioglitazone, Sitagliptin, Linagliptin), oral contraceptives (Ethinylestradiol, Levonorgestrel), and other medications (Simvastatin, Warfarin enantiomers, Ramipril, Digoxin, Hydrochlorothiazide, Torsemide). The graph compares AUC and Cmax values across these drugs.*

FDA Label Image

Glyxambi 05

A line chart showing the mean percentage change from baseline in HbA1c levels over 24 weeks for different treatments of empagliflozin and linagliptin combinations and monotherapies. The x-axis represents weeks from Baseline to Week 24, and the y-axis shows percentage change in HbA1c. Five groups are compared: Empa 25 mg/Lina 5 mg combination, Empa 10 mg/Lina 5 mg combination, Empa 25 mg alone, Empa 10 mg alone, and Lina 5 mg alone, with data points at Baseline, Week 6, 12, 18, and 24.*

FDA Label Image

Glyxambi 06

A line graph comparing the percentage of patients with events over 48 months between placebo and empagliflozin treatment groups. The x-axis shows time in months, and the y-axis shows the percentage of patients with events. The placebo group is represented by a solid line and the empagliflozin group by a dotted line. A table below the graph lists the number of subjects at risk at various time points for each group.*

FDA Label Image

Glyxambi 07

A Kaplan-Meier survival curve chart showing percentage of patients with event over months up to 48. Two groups are compared: Placebo (solid line) and All Empagliflozin (dotted line), with Placebo having a higher percentage of events over time. The number of subjects at risk for each group is listed below the x-axis at various months.*

FDA Label Image

Glyxambi 08

FDA Label Image

Glyxambi 09

Packaging label for Glyxambi 10 mg/5 mg film-coated tablets containing empagliflozin and linagliptin. The label indicates a package of 90 tablets for oral use. The labeler is Boehringer Ingelheim Pharmaceuticals, Inc., distributed with Eli Lilly and Company. Storage instructions and dosage guidance are present on the label.*

FDA Label Image

Glyxambi 10

Label for Glyxambi 25 mg/5 mg film-coated tablets containing empagliflozin and linagliptin. The label indicates the product is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company, with storage instructions and dosage information. It specifies 90 tablets per package and includes the NDC 0597-0164-90.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.